Toll‑like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model

Yin,Tao; He,Sisi; Wang,Yongsheng

doi:10.3892/mmr.2015.3885

Toll‑like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model

Authors:
- Tao Yin
- Sisi He
- Yongsheng Wang
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan 610041, P.R. China
Published online on: June 3, 2015 https://doi.org/10.3892/mmr.2015.3885
Pages: 3515-3520

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptors have been utilized in cancer therapeutic strategies in recent years. To the best of our knowledge, the systemic use of the toll‑like receptor 7/8 (TLR7/8) agonist has not been investigated in a breast cancer model. In the current study, tumor growth following drug therapy was examined. Immunofluorescence and TUNEL staining were performed in order to examine the tumor vasculature and apoptosis, respectively. In addition, immunohistochemistry was used to assess HMGB1 in tumor tissues. Activated CD4+ T cells in the peripheral blood were examined by flow cytometry. In the present study, it was identified that the TLR7/8 agonist, R848, exhibited a robust antitumoral effect. R848 reduced tumor vasculature and induced tumor cell apoptosis. In addition, R848 increased high mobility group box 1 expression in tumor tissues and activated CD4+ T cells in the peripheral blood. A synergistic antitumoral effect of R848 and the anti‑angiogenic agent, sunitinib, was observed. The present findings suggest that the TLR7/8 agonist may be a potential adjuvant to potentiate the effect of anti‑angiogenic therapy.

View Figures

View References

1	Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leuk Biol. 81:1–5. 2007. View Article : Google Scholar
2	Ridnour LA, Cheng RY, Switzer CH, et al: Toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity. Clin Cancer Res. 19:1340–1346. 2013. View Article : Google Scholar
3	Huang B, Zhao J, Li H, et al: Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
4	Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13:1050–1059. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chen CL, Tsukamoto H, Liu JC, et al: Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 123:2832–2849. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yoo KH, Lim TJ and Chang SG: Monthly intravesical bacillus Calmette-Guerin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute. Exp Ther Med. 3:221–225. 2012.PubMed/NCBI
7	Salaun B, Zitvogel L, Asselin-Paturel C, et al: TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71:1607–1614. 2011. View Article : Google Scholar : PubMed/NCBI
8	Jasani B, Navabi H and Adams M: Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine. 27:3401–3404. 2009. View Article : Google Scholar : PubMed/NCBI
9	Schon MP and Schon M: TLR7 and TLR8 as targets in cancer therapy. Oncogene. 27:190–199. 2008. View Article : Google Scholar : PubMed/NCBI
10	Weis SM and Cheresh DA: Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
11	Shojaei F, Wu X, Malik AK, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat Biotechnol. 25:911–920. 2007. View Article : Google Scholar : PubMed/NCBI
12	Shojaei F, Wu X, Qu X, et al: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 106:6742–6747. 2009. View Article : Google Scholar : PubMed/NCBI
13	Conley SJ, Gheordunescu E, Kakarala P, et al: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789. 2012. View Article : Google Scholar : PubMed/NCBI
14	Finke J, Ko J, Rini B, et al: MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol. 11:856–861. 2011. View Article : Google Scholar : PubMed/NCBI
15	Yang L, DeBusk LM, Fukuda K, et al: Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6:409–421. 2004. View Article : Google Scholar : PubMed/NCBI
16	Dovedi SJ, Melis MH, Wilkinson RW, et al: Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 121:251–259. 2013. View Article : Google Scholar
17	Sato Y, Goto Y, Narita N and Hoon DS: Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron. 2(Suppl 1): 205–214. 2009. View Article : Google Scholar : PubMed/NCBI
18	He W, Liu Q, Wang L, et al: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
19	Adams S, Kozhaya L, Martiniuk F, et al: Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 18:6748–6757. 2012. View Article : Google Scholar : PubMed/NCBI
20	Dewan MZ, Vanpouille-Box C, Kawashima N, et al: Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 18:6668–6678. 2012. View Article : Google Scholar : PubMed/NCBI
21	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
22	Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
23	Chung AS, Wu X, Zhuang G, et al: An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 19:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
24	Urbonaviciute V, Furnrohr BG, Meister S, et al: Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med. 205:3007–3018. 2008. View Article : Google Scholar : PubMed/NCBI
25	Dumitriu IE, Baruah P, Valentinis B, et al: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 174:7506–7515. 2005. View Article : Google Scholar : PubMed/NCBI
26	Messmer D, Yang H, Telusma G, et al: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 173:307–313. 2004. View Article : Google Scholar : PubMed/NCBI
27	Volpi C, Fallarino F, Bianchi R, et al: A GpC-rich oligonucleotide acts on plasmacytoid dendritic cells to promote immune suppression. J Immunol. 189:2283–2289. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ochi A, Graffeo CS, Zambirinis CP, et al: Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest. 122:4118–4129. 2012. View Article : Google Scholar : PubMed/NCBI
29	Ellerman JE, Brown CK, de Vera M, et al: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 13:2836–2848. 2007. View Article : Google Scholar : PubMed/NCBI
30	Mittal D, Saccheri F, Vénéreau E, et al: TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 29:2242–2252. 2010. View Article : Google Scholar : PubMed/NCBI
31	Sims GP, Rowe DC, Rietdijk ST, et al: HMGB1 and RAGE in Inflammation and Cancer. Annu Rev Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
32	Mitola S, Belleri M, Urbinati C, et al: Cutting Edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol. 176:12–15. 2006. View Article : Google Scholar
33	Huang J, Ni J, Liu K, et al: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar